Evidence map›Paper›PMID 41947552›Full record

ReviewClinical trials (London, England)2026

Bayesian analysis in confirmatory clinical trials: A narrative review and discussion of current practice.

Rebecca M Turner, Conor D Tweed, Trinh Duong, Deborah Ford, Michelle N Clements, Mahesh Kb Parmar, Anna Turkova, Ian R White

Abstract readReview
In one paragraph

Review in Clinical trials (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rebecca M TurnerMRC Clinical Trials Unit, University College London, London, UK.ORCID 0000-0001-7194-5464
Conor D TweedMRC Clinical Trials Unit, University College London, London, UK.
Trinh DuongMRC Clinical Trials Unit, University College London, London, UK.
Deborah FordMRC Clinical Trials Unit, University College London, London, UK.
Michelle N ClementsMRC Clinical Trials Unit, University College London, London, UK.
Mahesh Kb ParmarMRC Clinical Trials Unit, University College London, London, UK.
Anna TurkovaMRC Clinical Trials Unit, University College London, London, UK.
Ian R WhiteMRC Clinical Trials Unit, University College London, London, UK.ORCID 0000-0002-6718-7661

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBayesian methods allow trial investigators to combine evidence obtained within a clinical trial with relevant evidence that is available outside the trial. Bayesian analyses are now widely used in the drug development process, to inform internal 'go/no-go' decisions about planned studies, for example when deciding whether a drug should proceed from phase II to a phase III trial. However, Bayesian analyses are not commonly used for analysis of phase III (confirmatory) trials.

methodsIn this article, we performed a narrative review of confirmatory trials using Bayesian methods for their primary analysis, to explore which types of trials chose Bayesian methods, why they chose a Bayesian analysis and how the methods were used. We reviewed published papers over a 6-year period and explored the characteristics of trials using Bayesian methods for their primary analysis, their reasons for choosing a Bayesian analysis, whether any informative priors were used and if so how they were informed. Next, we selected four trials from the review as case studies and presented their motivation for using Bayesian methods and their Bayesian analyses in more detail.

resultsOur narrative review found that the number of Bayesian methods in confirmatory clinical trials has approximately doubled over the past 6 years, reflecting growing familiarity among investigators. Ninety-four papers were eligible for inclusion, presenting results from 69 separate trials. The most common reason given for choosing Bayesian methods was to make direct probability statements about the superiority and/or futility of the interventions evaluated; this was mentioned for 49% of trials. Flexibility in adapting the design or use of Bayesian stopping rules was another very common motivation, cited for 47% of trials. Borrowing information through informative priors was cited for a much smaller proportion (16%) of trials. The majority of trials (75%) specified vague or weakly informative priors for all parameters.

conclusionAmong the reasons given for choosing Bayesian methods, we consider the use of informative priors or making direct probability statements to be the strongest motivations for a Bayesian analysis, because there are no equivalent frequentist approaches. Making direct probability statements was the most common motivation provided, while informative priors were not often used. In settings with recruitment difficulties, we recommend considering borrowing relevant information, to gain power and precision. In all confirmatory trial settings, we recommend that Bayesian approaches are used only with careful justification, investigators make clear whether the methods and priors were pre-planned, and alternative frequentist approaches are considered.

Indexed as

Clinical Trials as TopicResearch DesignBayes TheoremClinical Trials, Phase III as TopicHumansBayesian analysisconfirmatory trialsphase III trialsreview

Identifiers

PMID41947552
PMCPMC13451585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.